These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31451969)

  • 1. Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors.
    Gerak LR; Maguire DR; France CP
    Handb Exp Pharmacol; 2020; 258():127-145. PubMed ID: 31451969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic.
    Manchikanti L; Sanapati J; Benyamin RM; Atluri S; Kaye AD; Hirsch JA
    Pain Physician; 2018 Jul; 21(4):309-326. PubMed ID: 30045589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replacement of current opioid drugs focusing on MOR-related strategies.
    Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
    Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Discriminative Stimulus Effects of Binary Mixtures of
    Flynn SM; France CP
    J Pharmacol Exp Ther; 2022 Mar; 380(3):171-179. PubMed ID: 34903563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.
    Kibaly C; Alderete JA; Liu SH; Nasef HS; Law PY; Evans CJ; Cahill CM
    Cell Mol Neurobiol; 2021 Jul; 41(5):899-926. PubMed ID: 33245509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.
    Walsh SL; Babalonis S
    Curr Top Behav Neurosci; 2017; 34():33-58. PubMed ID: 27356522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
    Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining opioids and non-opioids for pain management: Current status.
    Li JX
    Neuropharmacology; 2019 Nov; 158():107619. PubMed ID: 31029588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Insights into Mu Opioid Pharmacology.
    Pasternak GW; Childers SR; Pan YX
    Handb Exp Pharmacol; 2020; 258():89-125. PubMed ID: 31598835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.
    Maguire DR; France CP
    J Exp Anal Behav; 2023 Mar; 119(2):392-406. PubMed ID: 36759567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse Potential of Biased Mu Opioid Receptor Agonists.
    Negus SS; Freeman KB
    Trends Pharmacol Sci; 2018 Nov; 39(11):916-919. PubMed ID: 30343727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
    Zuurmond WW; Meert TF; Noorduin H
    Acta Anaesthesiol Belg; 2002; 53(3):193-201. PubMed ID: 12461829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin.
    Pergolizzi JV; LeQuang JA; Taylor R; Raffa RB;
    Postgrad Med; 2018 Jan; 130(1):1-8. PubMed ID: 29190175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis.
    Hassanien SH; Bassman JR; Perrien Naccarato CM; Twarozynski JJ; Traynor JR; Iula DM; Anand JP
    Drug Test Anal; 2020 Aug; 12(8):1212-1221. PubMed ID: 32415719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategies toward safer mu opioid receptor drugs for pain management.
    Ehrlich AT; Kieffer BL; Darcq E
    Expert Opin Ther Targets; 2019 Apr; 23(4):315-326. PubMed ID: 30802415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacology and opioid combinations.
    Pasternak GW
    Pain Med; 2012 Mar; 13 Suppl 1(s1):S4-11. PubMed ID: 22420604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids.
    Woolf CJ; Hashmi M
    Curr Opin Investig Drugs; 2004 Jan; 5(1):61-6. PubMed ID: 14983975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.
    Minervini V; Lu HY; Padarti J; Osteicoechea DC; France CP
    Psychopharmacology (Berl); 2018 Aug; 235(8):2245-2256. PubMed ID: 29785554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of fentanyl and other potent µ opioid agonist misuse in opioid-dependent individuals.
    Cicero TJ; Ellis MS; Paradis A; Ortbal Z
    Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1057-63. PubMed ID: 20597128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing safer analgesics: a focus on μ-opioid receptor pathways.
    Pergolizzi JV; LeQuang JA; Taylor R; Ossipov MH; Colucci D; Raffa RB
    Expert Opin Drug Discov; 2018 Oct; 13(10):965-972. PubMed ID: 30175624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.